Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > THTX Weekly Report Card

<< Previous

Bullboard Posts

Next >>

Comment by stockman75on May 30, 2021 3:04pm

121 Views

Post# 33294322

RE:RE:RE:RE:RE:THTX Weekly Report Card

Board did a great job of placating but I don't think they really agreed to the gravity or urgency of the matter. Voting off some directors would have gotten the message across and I think higher likelihood of corrective action. Our shareholder action not out of anger or spite. Simply out of an consequence of underperformance. Same as an underperforming employee.

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features